Diagnostic Testing at the Point-of-Care

OncoGenesis cervical screening products provide an integrated approach to cervical screening that improves all aspects of delivery from collection through sample processing and analysis.  Cervical samples collected via either OncoGenesis collectors or other clinical devices, are deposited into the OncoGenesis collection vial, which provides important preprocessing steps prior to analysis on the OncoGenesis instrument platform. OncoGenesis has developed a test platform that, working with the CerMark cervical screen test, provides clinicians with near immediate results while the patient is still in the office or clinic. Bridging the gap between the laboratory and point of care, the system meets the needs of both of these important market segments.

Point-of-Care System

Designed as a novel stand-alone, point-of-care system for multiplex detection, the platform utilizes novel microfluidic disc architecture, providing full sample processing and testing capabilities amenable to low resource, remote locations.

The system is designed to work even in developing countries where trained personnel or access to clinical laboratory equipment are not readily available.  Utilizing recent advances in microfluidic designs, it will provide maximum biological information of the cervical cytology specimen with minimal operator effort.  

  • Employs proprietary microfluidics technology
  • Simple and easy to use
  • Self-contained single patient test cartridge
  • Up to 6 patient test cartridges per run
  • Emerging World Markets
    The system is being developed to address those markets with the most need for low resource screening, i.e., emerging world markets where women are not being screened due to a lack of cytology labs and trained personnel.
  • Developed World Markets
    In the developed world, additional opportunities include POC Cartridgeuse in the doctor’s office, pharmacies and clinics, providing immediate results to patients.


Pending FDA clearance in the U.S.